Arthritis Studies Did Not Meet Criteria to Move Forward

ZymoGenetics, Inc. disclosed in an 8-K filing that the preliminary results of the Phase II clinical trials, Study 27298 and Study 27905 conducted by ZymoGenetics’s licensee, Merck Serono International SA, to study rheumatoid arthritis as an indication for the investigational drug atacicept did not meet the pre-specified level of disease control activity to support moving directly into Phase III clinical testing.
StreetInsider.com